Galderma diversified into aesthetic medicine products with the botulinum toxin Azzalure, strengthening the field in 2010 with the acquisition of Swedish medical device company Q-Med. Main brands include Restylane, Azzalure, Dysport, Alluzience, Sculptra and Relfydess. The company operates three core business units focused on comprehensive dermatology solutions.
Cyborg Score Rationale
Galderma has a market capitalization of 34.79 billion CHF and demonstrates solid operational performance in a high-growth dermatology market. Recent CFO appointment signals continued strategic investment, though execution of public company transition requires monitoring.
Top Insights
Recent IPO in 2024 provides capital for growth initiatives after private equity ownership since 2019
Three-pillar business model balances high-margin aesthetics with therapeutic dermatology and consumer skincare
Strategic brand portfolio includes industry-leading injectables (Restylane, Azzalure) with multi-billion treatment histories
Presence in ~90 countries with 4,600+ employees positions company for geographic expansion
Named Competitors
Botox — Botulinum toxin injectable for aesthetics and therapeutics
Jeuveau — Botulinum toxin aesthetic injectable
RHA — Hyaluronic acid dermal fillers and aesthetic treatments
Kybella — Deoxycholic acid injectable for submental fullness
Recent Developments
(February 2026) New CFO Luigi La Corte appointed effective May 1, 2026, bringing pharma and finance expertise
(April 2025) First Annual General Meeting held; approved 0.15 CHF dividend per share from capital reserves
(July 2024) Relfydess (relabotulinumtoxinA) received positive regulatory decision in Australia and European Union
Open the full interactive Galderma Group AG report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.